Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Pharmaceuticals has reported revenues of $1.28m for the third quarter ended 30 September 2010, compared to $3.65m for the same period in 2009.
Subscribe to our email newsletter
According to Inovio Pharmaceuticals, the decrease in the respective periods were mainly due to no revenue being recognised under the terminated Wyeth collaboration and licensing agreement as a result of the cancellation of the agreement in July 2009.
Inovio Pharma has posted a net loss of $1.41m for the third quarter 2010, or $0.01 loss per diluted share, compared to net loss of $2.95m, or $0.03 loss per diluted share, for the comparable period in 2009.
Inovio Pharma’s loss from operations was $4.56m, compared to $3.6m for the comparable period in 2009.
The company has posted a revenue of $3.78m for the nine months ended 30 September 2010, compared to $6.51m for the year ago period.
For the nine months ended 30 September 2010, Inovio Pharma posted a net loss of $11.32m, or $0.11 loss per diluted share, compared to $17.07m, or $0.26 loss per diluted share, for the year ago period.
The company’s loss from operations for the nine months ended 30 September 2010 was $13.94m, compared to $10.15m for the year ago period.